Completed genome is first step to tackling Tasmanian devil facial tumours

Uncovering the mutations found in transmissible cancer in the endangered Tasmanian devil could help conservation efforts

Completed genome is first step to tackling Tasmanian devil facial tumours

The Tasmanian devil is at risk of extinction in the wild due to a transmissible facial cancer. Next generation sequencing could guide conservation efforts by tracing the spread of the disease.

Researchers from the Wellcome Trust Sanger Institute and Illumina have used next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil and will use this to find genetic mutations in the transmissible cancer that is ravaging its population.

The results open the door for new research to pick out those specific mutations that drive the cancer and will lay the foundation for ongoing work to trace the spread of disease and inform the development of preclinical tests, conservation strategies and disease therapies. The announcement is made today by Sanger Institute researcher, Dr Elizabeth Murchison, at the AMATA 2010 Conference in Hobart, Tasmania.

The Tasmanian devil is the largest carnivorous marsupial and is native to the island of Tasmania. The species is at risk of extinction in the wild due to a transmissible facial cancer, which is spread between devils by the transfer of cancer cells by biting. The cancerous cells from the first devil then colonise the bitten animal, which usually dies within months of the appearance of symptoms. In the 14 years since the disease was first observed, the devil population has declined by more than 80 per cent.

Tasmanian devil facial tumour is almost unique in cancers of the animal kingdom in that it is transmitted by direct transplantation of cancer cells from animal to animal.

"This sequence is invaluable and comes at a crucial time. By comparing our draft sequence with samples taken from many hundreds of devils suffering from this cancer, we can begin to look at the spread of the disease, quite literally, by identifying geographical routes and barriers in its transmission. This knowledge could ultimately shape the ongoing conservation efforts in Tasmania."

"It took 10 years to sequence the draft human genome; the devil took just two months using this new technology. We are entering a new era where genome sequencing can be applied to some of our most pressing problems in real time."

Dr Elizabeth Murchison, from the Sanger Institute's Cancer Genome Project

As well as producing the draft genome sequence for a healthy Tasmanian devil, named Salem, the team has sequenced two independent tumour samples taken from devils with the disease, which will now be analysed. This will allow the researchers to pinpoint those mutations that are present only in the cancerous samples.

The next step will be to sequence many more Tasmanian devil facial tumour samples. By generating profiles of the mutations present in these cancers, the team hopes to improve understanding of the disease and its spread.

"This sequence is not only a boon to the efforts to protect this endangered species. We believe that this research, the first of its kind to look at this very unusual form of transmissible cancer, will also teach us important lessons about the evolution of cancers. What we are observing is not just a class of cancer that afflicts the Tasmanian devil; we are actually peering into the very same cancer that originated in just one devil, some 20 years ago - a cancer that has long survived its original host."

"In research terms, this is truly unique - it will provide an unprecedented window into the evolution of cancer."

Professor Mike Stratton, Director of the Sanger Institute and joint head of the Cancer Genome Project

Sequencing, de novo assembly and analysis of genetic variation of the three genomes has been undertaken jointly by scientists at the Sanger Institute and Illumina.

"We're excited about what this project means not just to the future of this very rare and endangered species and this unusual cancer. It is wonderful to see our sequencing platform opening a world of new possibilities for scientists to get at the root causes and manifestations of disease through close collaborations like this."

David Bentley, Chief Scientist at Illumina

Notes to Editors
Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

From childhood cancer to mapping human development: Pioneering scientist awarded 2019 Foulkes Foundation medal
Congratulations to Professor Muzlifah Haniffa, who has been recognised for her work on the immune system and childhood cancer
Dr Sam Behjati wins Liddy Shriver Early Career Research Award
Congratulations to Sanger Institute cancer researcher, Dr Sam Behjati, who has been recognised for his work in sarcoma cancer genomics
New malaria drug targets identified in liver stage of life cycle
Hope that new liver-stage drugs will help to counter the threat of antimicrobial resistance to current blood-stage medicines